The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome (Q34207531)

31 July 2017

title

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome (English)

1 reference

31 July 2017

1 reference

David C Dale

1

1 reference

31 July 2017

Audrey Anna Bolyard

2

1 reference

31 July 2017

Merideth L Kelley

3

1 reference

31 July 2017

Ernest C Westrup

4

1 reference

31 July 2017

Vahagn Makaryan

5

1 reference

31 July 2017

Andrew Aprikyan

6

1 reference

31 July 2017

Brent Wood

7

1 reference

31 July 2017

Frank J Hsu

8

1 reference

31 July 2017

language of work or name

English

0 references

publication date

11 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

118

1 reference

31 July 2017

issue

18

1 reference

31 July 2017

page(s)

4963-4966

1 reference

AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34 hematopoietic progenitor cells by AMD3100.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3673761

The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment

28 October 2018

1 reference

12 December 2020

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

Myelokathexis: chronic neutropenia with hyperplastic bone marrow and hypersegmented neutrophils in two siblings

1 reference

12 December 2020

"MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE

1 reference

12 December 2020

10.1182/BLOOD-2011-06-360586

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference